Hartung HP - Search Results

1

Bleak prospects for primary progressive multiple sclerosis therapy: downs and downs, but a glimmer of hope.

Hartung HP, Aktas O. Hartung HP, et al. Ann Neurol. 2009 Oct;66(4):429-32. doi: 10.1002/ana.21880. Ann Neurol. 2009. PMID: 19847907 No abstract available.

2

Impact of HMG-CoA reductase inhibition on brain pathology.

Zipp F, Waiczies S, Aktas O, Neuhaus O, Hemmer B, Schraven B, Nitsch R, Hartung HP. Zipp F, et al. Among authors: hartung hp. Trends Pharmacol Sci. 2007 Jul;28(7):342-9. doi: 10.1016/j.tips.2007.05.001. Epub 2007 Jun 15. Trends Pharmacol Sci. 2007. PMID: 17573124 Review.

3

Toward the development of rational therapies in multiple sclerosis: what is on the horizon?

Hemmer B, Hartung HP. Hemmer B, et al. Among authors: hartung hp. Ann Neurol. 2007 Oct;62(4):314-26. doi: 10.1002/ana.21289. Ann Neurol. 2007. PMID: 17969020 Review.

4

Neuromyelitis and more: the unfolding spectrum of aquaporin 4-related neurological diseases.

Aktas O, Hartung HP. Aktas O, et al. Among authors: hartung hp. J Neurol. 2009 Nov;256(11):1906-8. doi: 10.1007/s00415-009-5317-x. J Neurol. 2009. PMID: 19768482 No abstract available.

5

Development of oral cladribine for the treatment of multiple sclerosis.

Hartung HP, Aktas O, Kieseier B, Giancarlo Comi GC. Hartung HP, et al. J Neurol. 2010 Feb;257(2):163-70. doi: 10.1007/s00415-009-5359-0. J Neurol. 2010. PMID: 19921304 Review.

6

Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis.

Aktas O, Kieseier B, Hartung HP. Aktas O, et al. Among authors: hartung hp. Trends Neurosci. 2010 Mar;33(3):140-52. doi: 10.1016/j.tins.2009.12.002. Epub 2010 Jan 4. Trends Neurosci. 2010. PMID: 20045200 Review.

7

Oral therapies for multiple sclerosis: are we there yet?

Hartung HP, Aktas O. Hartung HP, et al. Lancet Neurol. 2010 May;9(5):454-7. doi: 10.1016/S1474-4422(10)70088-0. Lancet Neurol. 2010. PMID: 20398852 No abstract available.

8

Fingolimod is a potential novel therapy for multiple sclerosis.

Aktas O, Küry P, Kieseier B, Hartung HP. Aktas O, et al. Among authors: hartung hp. Nat Rev Neurol. 2010 Jul;6(7):373-82. doi: 10.1038/nrneurol.2010.76. Epub 2010 Jun 15. Nat Rev Neurol. 2010. PMID: 20551946 Review.

9

Considerations on discontinuing natalizumab for the treatment of multiple sclerosis.

Berger JR, Centonze D, Comi G, Confavreux C, Cutter G, Giovannoni G, Gold R, Hartung HP, Lublin F, Miravalle A, Montalban X, O'Connor P, Olsson T, Polman CH, Stuve O, Wolinsky JS, Ziemssen T. Berger JR, et al. Among authors: hartung hp. Ann Neurol. 2010 Sep;68(3):409-11. doi: 10.1002/ana.22083. Ann Neurol. 2010. PMID: 20818795 No abstract available.

10

Evolution of multiple sclerosis treatment: next generation therapies meet next generation efficacy criteria.

Hartung HP, Aktas O. Hartung HP, et al. Lancet Neurol. 2011 Apr;10(4):293-5. doi: 10.1016/S1474-4422(11)70043-6. Lancet Neurol. 2011. PMID: 21397566 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,122 results

Search Page